Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib with Bendamustine, Rituximab, and Cytarabine in Untreated Mantle Cell Lymphoma
NCT04115631Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Dec 2019
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL) (3 arms), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Composite of PET/CT Complete Response and Peripheral Blood Minimal Residual Disease Negative Rate. Started Dec 2019; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04115631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115631.